166 related articles for article (PubMed ID: 36252280)
1. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
[TBL] [Abstract][Full Text] [Related]
2. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
Yan J; Zhou DM; Shao XY; Xu Y; Chen B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
[No Abstract] [Full Text] [Related]
3. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
[No Abstract] [Full Text] [Related]
5. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Alzahrani K; Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin R; Qazilbash MH
Br J Haematol; 2024 May; 204(5):1944-1952. PubMed ID: 38448009
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
[TBL] [Abstract][Full Text] [Related]
8. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.
Guo W; Zhan A; Mery DE; Munshi MN; Makhoul O; Baily C; Zangari M; Tricot G; Peng H; Shaughnessy JD
Blood Adv; 2023 Nov; 7(21):6676-6684. PubMed ID: 37756524
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
10. [Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].
Xu Y; Shen XX; Jin YY; Li JY; Chen LJ; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):749-754. PubMed ID: 38049319
[No Abstract] [Full Text] [Related]
11. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic Value of A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma].
Wang Y; Yue LL; Zeng PY; Wu CY; Han Y; Song Y; Jin QQ; Jiang HY; Chai Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1779-1784. PubMed ID: 36476903
[TBL] [Abstract][Full Text] [Related]
13. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
15. Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
Ozaki S; Handa H; Koiso H; Saitoh T; Sunami K; Ishida T; Suzuki K; Narita T; Iida S; Nakamura Y; Suzuki K; Nishimura N; Murakami H; Shimizu K
J Cancer Res Clin Oncol; 2022 Jan; 148(1):191-203. PubMed ID: 34080068
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Schavgoulidze A; Lauwers-Cances V; Perrot A; Cazaubiel T; Chretien ML; Moreau P; Facon T; Leleu X; Karlin L; Stoppa AM; Decaux O; Belhadj K; Arnulf B; Mohty M; Ariette CM; Fohrer-Sonntag C; Lenain P; Marolleau JP; Tiab M; Araujo C; Orsini-Piocelle F; Jaccard A; Roussel M; Benboubker L; Eveillard JR; Dib M; Divoux M; Attal M; Avet-Loiseau H; Corre J
Haematologica; 2023 May; 108(5):1374-1384. PubMed ID: 36172814
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis.
Chen H; Shi H; Zhou N; Yu W; Wu L; Peng R; Wei W; Wang D; Zhou F
Eur J Haematol; 2023 Mar; 110(3):229-235. PubMed ID: 36366975
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].
Lu J; Du J; Fu WJ; He HY; Li L; Li R; Zhou LL; Jiang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):475-479. PubMed ID: 28655089
[No Abstract] [Full Text] [Related]
19. Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients.
Cao Y; Gong Y; Zhou X; Sun C
Hematology; 2023 Dec; 28(1):2208914. PubMed ID: 37145015
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
